Contributions
Abstract: EP1643
Type: Poster Sessions
Abstract Category: Therapy - Long-term treatment monitoring
Background: Alemtuzumad (Alem) is a monoclonal anti-CD52 antibody which depletes circulating lymphocytes followed by their reconstitution. Alem is currently used as a treatment for active relapsing remitting multiple sclerosis (RRMS) and administered in two courses one year apart.
Objective: We evaluated the efficacy of Alem treatment in active RRMS in real-life settings assessing treatment effects on relapse rate and disability progression.
Methods: We performed a retrospective review of 35 RRMS patients (19:16 f:m), with mean disease duration of 14.2 years, mean EDSS of 4.6 and median age of 38 years. All patients treated with Alem and had an average follow up of 24 months post infusion.
Results: The mean annualized relapse rate at 1 year prior Alem treatment was 2.06 and 1.63 at 2 years prior the Treatment. At 2 years of post-infusion follow-up, The mean annualized relapse rate was 0.54. The mean change in number of relapses within 2 years from start Treatment from 2 year prior treatment -1.09, (P value < .0001). The mean EDSS at the baseline was 4.57, EDSS after 2 years 4.47 mean change was -0.1. There was no significant EDSS Change from baseline (P value < .0.6177).
Treatment related adverse events: Total number of 13 patients (13/35) had adverse events. The adverse events profile recorded: 7 patients were diagnosed with Urinary tract infection, 4 patients were diagnosed with cutaneous Herpes-Zoster, 2 patients were diagnosed with Thyroid abnormality and 1 patient was diagnosed with Gastric Carcinoma.
Conclusion: Alem treatment given with one cycle or more reduced significantly the annualized relapse rate and prevented disability progression during two years of follow-up. Treatment-related adverse events were minor and tolerability of treatment was high.
Disclosure: Anat Achiron received research support from Biogen Idec, MercSerono, SanofiGenzayme, Roch and Bayer
Abstract: EP1643
Type: Poster Sessions
Abstract Category: Therapy - Long-term treatment monitoring
Background: Alemtuzumad (Alem) is a monoclonal anti-CD52 antibody which depletes circulating lymphocytes followed by their reconstitution. Alem is currently used as a treatment for active relapsing remitting multiple sclerosis (RRMS) and administered in two courses one year apart.
Objective: We evaluated the efficacy of Alem treatment in active RRMS in real-life settings assessing treatment effects on relapse rate and disability progression.
Methods: We performed a retrospective review of 35 RRMS patients (19:16 f:m), with mean disease duration of 14.2 years, mean EDSS of 4.6 and median age of 38 years. All patients treated with Alem and had an average follow up of 24 months post infusion.
Results: The mean annualized relapse rate at 1 year prior Alem treatment was 2.06 and 1.63 at 2 years prior the Treatment. At 2 years of post-infusion follow-up, The mean annualized relapse rate was 0.54. The mean change in number of relapses within 2 years from start Treatment from 2 year prior treatment -1.09, (P value < .0001). The mean EDSS at the baseline was 4.57, EDSS after 2 years 4.47 mean change was -0.1. There was no significant EDSS Change from baseline (P value < .0.6177).
Treatment related adverse events: Total number of 13 patients (13/35) had adverse events. The adverse events profile recorded: 7 patients were diagnosed with Urinary tract infection, 4 patients were diagnosed with cutaneous Herpes-Zoster, 2 patients were diagnosed with Thyroid abnormality and 1 patient was diagnosed with Gastric Carcinoma.
Conclusion: Alem treatment given with one cycle or more reduced significantly the annualized relapse rate and prevented disability progression during two years of follow-up. Treatment-related adverse events were minor and tolerability of treatment was high.
Disclosure: Anat Achiron received research support from Biogen Idec, MercSerono, SanofiGenzayme, Roch and Bayer